Biomedical subjects
Publications and source records attributed to J Heim.
An hypothyroidism is discovered. Secondary, a primary adrenal insufficiency is proved. Therefore, we can affirm the Schmidt's syndrome. The anti-adrenal and anti-thyroid antibodies are positive; when the glucocorticoid treatment is begun, the dose of thyroxine treatment must be decreased. That point allows us to discuss the interrelationships between thyroid and adrenals.
Explore the source record for details and available documents.
HLA-A, B, C antigens were studied in 86 white european patients with Graves' disease, using a lymphocyte toxicity microtechnique and the results were compared with those obtained in 356 healthy subjects. HLA-D (DR) antigens were studied by the same technique after prolonged incubation and the results were compared with those of 100 healthy controls. The incidence of DRw3 was 51.16% in the patients as against 20% in controls, the difference being highly significant (pc--PC less than 0.0003) - corrected p = p multiplied by the number of antigens tested. There was also a significant (pc less than 0.001) increase in HLA-BB: 44.19% against 22.47%, and in HLA-A1: 40.7% against 28.93% (pc less than 0.03). Conversely, there was a decrease in the incidence of HLA-B12: 12.79% against 31.74% (pc less than 0.01). B8 was found to be associated with DRw3 in 37 of the 86 patients, but in only 13 of the 100 controls (p less than 0.00003). There was no correlation between the HLA antigens and the clinical features of the disease (presence or absence of goitre and exophthalmos, severity of clinical or biological symptoms). These results are in agreement with those of other studies reporting an increase in HLA-B8. The increase in HLA-A1 is probably due to an accentuation of the unbalanced linkage with B8. The major finding was the predominance of the DRw3 antigen, also found by other authors working with a mixed lymphocyte culture. It seems therefore possible that the putative Graves' disease susceptibility antigen is present on the sixth chromosome, near to HLA-D (DR).
Explore the source record for details and available documents.
Explore the source record for details and available documents.
HLA-A, -B, and -C antigens were tested by a standard lymphocyte microcytotoxicity technique in 86 Caucasians patients from western France with Graves' disease, and the data were compared with findings in 356 healthy controls. For HLA-DR antigen typing performed by lymphocyte microcytotoxicity testing using a long incubation time, the data were compared to findings in 100 healthy controls. An increase was found in the frequency of HLA-DRw3 [51.16% of patients vs. 20% of controls, corrected P (Pc) < 0.0003; relative risk (rr), 4.19) associated with an increased frequency of HLA-B8 (44.19% of patients vs. 22.47% of controls; Pc < 0.001; rr, 2.73) and HLA-A1 (40.7% of patients vs. 28.93% of controls; Pc < 0.03; rr, 1.71). In contrast, a diminished frequency was found for HLA-B12 (12.79% vs. 31.74%; Pc < 0.01). The antigen combination B8-DRw3 was noted in 37 of the 86 Graves' disease patients compared with 13 of 100 controls (Pc < 0.00003). No association was observed between HLA antigens and the different manifestations of the disease, such as the presence of goiter and/or exophthalmos, or the severity of clinical or biochemical signs. The present findings confirm the reported increase in the frequency of HLA-B8 in patients with Graves' disease. The most striking finding was the prevalence of HLA-DRw3, which, together with recent reports on lymphocyte-defined D locus determinants pointing to an increase frequency of HLA-Dw3, suggests that the gene or genes conferring susceptibility to Graves' disease may be located close to the HLA-D (DR) region of the sixth chromosome.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A synthesis has been attempted to explain the metabolic action of oestrogen-progestogens: and their action on carbohydrates, triglycerides, cholesterol, lipoproteins and coagulation has been reviewed. Carbohydrate tolerance can evolve in different ways, depending on the case. On the one hand hyperglycaemia, which is provoked by taking carbohydrates by mouth in a primitively pathological way, can be improved while on the other hand there can be diminution in carbohydrate tolerance in other cases. Two factors, however, remain constant, hyperinsulinism and resistance to insulin. There is no way of predicting how carbohydrate tolerance will behave. That is why pills that contain oestrogens and progestogens, even if they are "mini-dose" pills, are contra-indicated for women who have pancreatic diabetes. Pills with a high oestrogen content raise the triglycerides, while those which have a higher progestogen content tend to raise the blood cholesterol levels. High-density lipoprotein tends to be raised with an oestrogenic milieu and lowered with progestogens or with pills that have a strong progestogen content.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.